Have your own idea? Try our Stock Screener
U.S. Life Sciences Industry Analysis
UpdatedJan 31, 2026
DataAggregated Company Financials
Companies62
- 7D-5.9%
- 3M0.6%
- 1Y-3.9%
- YTD-2.3%
Over the last 7 days, the Life Sciences industry has dropped 5.9%, driven by a pullback from Thermo Fisher Scientific of 7.6%. In contrast, Rapid Micro Biosystems has gained 7.5%. However, the industry is down 3.9% over the past year. As for the next few years, earnings are expected to grow by 17% per annum.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 01 Feb 2026 | US$662.4b | US$147.0b | US$12.6b | 34x | 52.6x | 4.5x |
| Tue, 30 Dec 2025 | US$665.3b | US$145.8b | US$12.4b | 36.2x | 53.8x | 4.6x |
| Thu, 27 Nov 2025 | US$686.1b | US$145.8b | US$12.5b | 37.4x | 55.1x | 4.7x |
| Sat, 25 Oct 2025 | US$663.2b | US$145.3b | US$14.5b | 34.1x | 45.9x | 4.6x |
| Mon, 22 Sep 2025 | US$573.4b | US$144.3b | US$14.6b | 30.7x | 39.4x | 4x |
| Wed, 20 Aug 2025 | US$582.2b | US$144.2b | US$14.5b | 29.3x | 40.2x | 4x |
| Fri, 18 Jul 2025 | US$525.0b | US$142.9b | US$9.1b | 35.6x | 57.5x | 3.7x |
| Sun, 15 Jun 2025 | US$526.1b | US$142.9b | US$9.2b | 35.7x | 57.4x | 3.7x |
| Tue, 13 May 2025 | US$505.6b | US$142.7b | US$9.6b | 36x | 52.7x | 3.5x |
| Thu, 10 Apr 2025 | US$486.3b | US$142.5b | US$9.9b | 35.2x | 48.9x | 3.4x |
| Sat, 08 Mar 2025 | US$607.6b | US$143.1b | US$9.8b | 42.5x | 62.3x | 4.2x |
| Mon, 03 Feb 2025 | US$691.5b | US$143.0b | US$10.4b | 41.1x | 66.5x | 4.8x |
| Wed, 01 Jan 2025 | US$650.7b | US$142.4b | US$10.2b | 44.2x | 63.6x | 4.6x |
| Fri, 29 Nov 2024 | US$669.3b | US$142.4b | US$10.2b | 44.5x | 65.4x | 4.7x |
| Sun, 27 Oct 2024 | US$674.4b | US$142.0b | US$8.3b | 35.4x | 81.6x | 4.7x |
| Tue, 24 Sep 2024 | US$746.6b | US$141.8b | US$8.5b | 37.7x | 87.9x | 5.3x |
| Thu, 22 Aug 2024 | US$747.2b | US$141.9b | US$8.3b | 37.9x | 90.1x | 5.3x |
| Sat, 20 Jul 2024 | US$680.3b | US$141.2b | US$12.2b | 39.9x | 55.7x | 4.8x |
| Mon, 17 Jun 2024 | US$695.0b | US$141.3b | US$12.2b | 37.9x | 57.1x | 4.9x |
| Wed, 15 May 2024 | US$724.6b | US$141.5b | US$12.6b | 39.4x | 57.7x | 5.1x |
| Fri, 12 Apr 2024 | US$727.0b | US$142.0b | US$12.8b | 43x | 56.8x | 5.1x |
| Sun, 10 Mar 2024 | US$754.1b | US$142.1b | US$12.8b | 44.5x | 58.8x | 5.3x |
| Tue, 06 Feb 2024 | US$705.3b | US$141.9b | US$12.8b | 38.6x | 54.9x | 5x |
| Thu, 04 Jan 2024 | US$683.5b | US$153.8b | US$14.2b | 36x | 48.2x | 4.4x |
| Sat, 02 Dec 2023 | US$645.5b | US$153.8b | US$14.0b | 35.5x | 46.1x | 4.2x |
| Mon, 30 Oct 2023 | US$565.9b | US$153.8b | US$11.3b | 29.2x | 50.3x | 3.7x |
| Wed, 27 Sep 2023 | US$667.0b | US$154.6b | US$11.2b | 33.5x | 59.5x | 4.3x |
| Fri, 25 Aug 2023 | US$707.8b | US$154.6b | US$11.2b | 32.9x | 63.2x | 4.6x |
| Sun, 23 Jul 2023 | US$741.4b | US$155.5b | US$12.7b | 29.4x | 58.4x | 4.8x |
| Tue, 20 Jun 2023 | US$704.3b | US$152.4b | US$12.5b | 29.3x | 56.3x | 4.6x |
| Thu, 18 May 2023 | US$673.1b | US$152.4b | US$12.6b | 28.4x | 53.3x | 4.4x |
| Sat, 15 Apr 2023 | US$737.2b | US$154.6b | US$10.8b | 30.5x | 68.2x | 4.8x |
| Mon, 13 Mar 2023 | US$693.6b | US$154.5b | US$10.9b | 29.6x | 63.9x | 4.5x |
| Wed, 08 Feb 2023 | US$763.2b | US$155.6b | US$9.1b | 32x | 83.8x | 4.9x |
Price to Earnings Ratio
83.8x
Current Industry PE
- Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 52.6x which is lower than its 3-year average PE of 59.3x.
- The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 11% per year over the last three years, while revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.28% | |
| Healthcare | -2.46% | |
| Life Sciences | -5.93% | |
| Clinical Research and Equipment | -5.93% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| RPID Rapid Micro Biosystems | US$4.43 | 7.5% +US$13.7m | 147.5% | PS6.4x | |
| CSBR Champions Oncology | US$7.31 | 8.3% +US$7.8m | -33.5% | PE40.8x | |
| LFCR Lifecore Biomedical | US$8.69 | 1.3% +US$4.1m | 46.3% | PS2.5x |
